Home > Formulary : Paediatric > Recent Decisions > 2024 >
Decisions 21st May
New Drug Requests:
- Drospirenone (Slynd) (TLS Blue) second line progesterone only pill
- Ethinylestradiol / drospirenone (Yacella and Dretine) (TLS Blue) second line combined hormonal contraceptive
- Ethinylestradiol / gestodene (Millinette 30/75 and 20/75) (TLS Blue) second line combined hormonal contraceptive. Femodene ED brand also approved for use where the inactive tablets may add benefit to support compliance only.
- Doublebase Once gel (TLS Blue) as a second line emollient option for chronic severe inflammatory hand conditions where first line emollient options have not controlled disease.
- Adex gel (TLS Blue) as a second line emollient option for facial inflammatory conditions - eczema, psoriasis, perioral dermatitis, seborrhoeic dermatitis. For use in patients with facial inflammatory conditions where topical steroid sparing is required but topical calcineurin inhibitors are not tolerated/effective or reduced topical corticosteroid frequencies are giving flare and alternative options have not controlled disease.
- Spironolactone (oral) (TLS Amber Specialist Initiated) for treatment of acne vulgaris in female patients
Shared Care Protocols:
- Sodium valproate SCP updated
Traffic light status changes:
- Bendroflumethiazide – TLS changed to Amber Specialist Initiated
Other decisions and discussions:
- Nutrizym 22 pancreatic enzyme approved for inclusion onto Joint Formulary as TLS Amber Specialist Initiated
- Migraine and neuropathic pain indications for valproate removed from Joint Formulary as no longer recommended
- Canesten HC cream approved for use as an alternative to Daktacort cream as TLS Green
- Klean-Prep discontinued and removed from the Joint Formulary.
- Miconazole pessary discontinued and removed the Joint Formulary.